Tretinoin for thrombocytopenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Dec 2025: Trial started, NCT07586826
  2. 14 May 2026: Trial registered, NCT07586826

The trials

NCT07586826: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

State
Under way
Phase
Phase 2
People
220 planned
Started
22 Dec 2025
Primary completion
31 Oct 2027
Arms
Romiplostim N01 Plus ATRA
Results
None posted
  1. 22 Dec 2025: Trial started
  2. 14 May 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Aberel, Altreno, Avita, All-trans retinoic acid, Eudyna, Kerlocal, Oristar rna, Renova, Retin a, Retin-a, Twyneo component tretinoin, Veltin component tretinoin, Vesanoid, all trans Retinoic Acid.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.